Craig joined Oxford Science Enterprises in February 2022, bringing over 20 years of drug discovery and development expertise, with vast experience as a research scientist managing initial target selection through to Phase 2 clinical studies.
At OSE, Craig supports the growth and development of Life Science businesses, the identification of new opportunities, and formation of new spinouts.
He joined from C4X Discovery where he was Chief Scientific Officer and an Executive Board Member for more than six years, guiding its transition from a technology-based company to a therapeutics business. Craig has also worked at a number of biotechnology companies supporting multiple financing deals, the creation and management of strategic collaborations and licensing deals with Pharma.
Craig holds a PhD in Respiratory Medicine from Birmingham University and a first-class Biochemistry degree from the University of Surrey.
